These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 86997)

  • 1. The attenuation of delta 9-tetrahydrocannabinol and morphine of the quasi-morphine withdrawal syndrome in rats.
    Zaluzny SG; Chesher GB; Jackson DM; Malor R
    Psychopharmacology (Berl); 1979 Mar; 61(2):207-16. PubMed ID: 86997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of morphine, naloxone, buprenorphine, butorphanol, haloperidol and imipramine on morphine withdrawal signs in cynomolgus monkeys.
    Fukase H; Fukuzaki K; Koja T; Nagata R; Lukas SE
    Psychopharmacology (Berl); 1994 Dec; 116(4):396-400. PubMed ID: 7701039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice.
    Lichtman AH; Sheikh SM; Loh HH; Martin BR
    J Pharmacol Exp Ther; 2001 Sep; 298(3):1007-14. PubMed ID: 11504797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endogenous cannabinoid, 2-arachidonoylglycerol, attenuates naloxone-precipitated withdrawal signs in morphine-dependent mice.
    Yamaguchi T; Hagiwara Y; Tanaka H; Sugiura T; Waku K; Shoyama Y; Watanabe S; Yamamoto T
    Brain Res; 2001 Aug; 909(1-2):121-6. PubMed ID: 11478928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clonidine suppresses methylxanthine induced quasi-morphine withdrawal syndrome.
    Grant SJ; Redmond DE
    Pharmacol Biochem Behav; 1982 Oct; 17(4):655-8. PubMed ID: 6184732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ethopharmacological analysis of naloxone-precipitated morphine withdrawal syndrome in rats: a newly-developed "etho-score".
    Fdez Espejo E; Cador M; Stinus L
    Psychopharmacology (Berl); 1995 Nov; 122(2):122-30. PubMed ID: 8848527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The quasi-morphine withdrawal syndrome: effect of cannabinol, cannabidiol and tetrahydrocannabinol.
    Chesher GB; Jackson DM
    Pharmacol Biochem Behav; 1985 Jul; 23(1):13-5. PubMed ID: 2994117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of naloxone-induced withdrawal in morphine dependent mice by 1-trans-delta9-tetrahydrocannabinol.
    Bhargava HN
    Eur J Pharmacol; 1976 Mar; 36(1):259-62. PubMed ID: 944134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of 5-HT3 receptor antagonists on behavioural measures of naloxone-precipitated opioid withdrawal.
    Higgins GA; Nguyen P; Joharchi N; Sellers EM
    Psychopharmacology (Berl); 1991; 105(3):322-8. PubMed ID: 1839177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of morphine and delta-9-tetrahydrocannabinol on motor activity in rats.
    Tulunay FC; Ayhan IH; Sparber SB
    Psychopharmacology (Berl); 1982; 78(4):358-60. PubMed ID: 6296906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dorsal and median raphe serotonergic system lesion does not alter the opiate withdrawal syndrome.
    Caillé S; Espejo EF; Koob GF; Stinus L
    Pharmacol Biochem Behav; 2002 Jul; 72(4):979-86. PubMed ID: 12062589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The adenosinergic system is involved in sensitization to morphine withdrawal signs in rats-neurochemical and molecular basis in dopaminergic system.
    Listos J; Baranowska-Bosiacka I; Wąsik A; Talarek S; Tarnowski M; Listos P; Łupina M; Antkiewicz-Michaluk L; Gutowska I; Tkacz M; Pilutin A; Orzelska-Górka J; Chlubek D; Fidecka S
    Psychopharmacology (Berl); 2016 Jun; 233(12):2383-97. PubMed ID: 27087433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tetrahydrocannabinol-attenuated abstinence and induced rotation in morphine-dependent rats: possible involvement of dopamine.
    Hine B; Friedman E; Torrelio M; Gershon S
    Neuropharmacology; 1975 Aug; 14(8):607-10. PubMed ID: 1237098
    [No Abstract]   [Full Text] [Related]  

  • 14. Modulation of oral morphine antinociceptive tolerance and naloxone-precipitated withdrawal signs by oral Delta 9-tetrahydrocannabinol.
    Cichewicz DL; Welch SP
    J Pharmacol Exp Ther; 2003 Jun; 305(3):812-7. PubMed ID: 12606610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time course of the effects of naturally occurring cannabinoids on morphine abstinence syndrome.
    Bhargava HN
    Pharmacol Biochem Behav; 1978 Jan; 8(1):7-11. PubMed ID: 564515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Further studies of the role of opioid receptors in the nigra in the morphine withdrawal syndrome.
    Baumeister AA; Richard AL; Richmond-Landeche L; Hurry MJ; Waguespack AM
    Neuropharmacology; 1992 Sep; 31(9):835-41. PubMed ID: 1359441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of antipsychotic and antianxiety drugs on the morphine abstinence syndrome in rats.
    Baldino F; Cowan A; Geller EB; Adler MW
    J Pharmacol Exp Ther; 1979 Jan; 208(1):63-6. PubMed ID: 32386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of ibogaine on naloxone-precipitated withdrawal syndrome in chronic morphine-dependent rats.
    Dzoljic ED; Kaplan CD; Dzoljic MR
    Arch Int Pharmacodyn Ther; 1988; 294():64-70. PubMed ID: 3233054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Voluntary oral morphine self-administration in rats: effect of haloperidol or ondansetron.
    Borg PJ; Taylor DA
    Pharmacol Biochem Behav; 1994 Mar; 47(3):633-46. PubMed ID: 8208784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term effects of neonatal exposure to isobutylmethylxanthine. II. Attenuation of acute morphine withdrawal in mature rats.
    Neal BS; Messing RB; Sparber SB
    Psychopharmacology (Berl); 1991; 103(3):398-406. PubMed ID: 1711704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.